Vieira Roberto Wandenkolk sold $674K of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $80.89 ($80.73–$81.52, $0.67M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Nov 5, 2026, 12:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale is modest in size relative to the insider's remaining stake and may not materially affect price.

02

Market read

A routine insider sale with limited market impact; traders may note the transaction but unlikely to act on it.

03

What to watch

Upcoming clinical trial data or partnership announcements could offset the negative perception of the insider sale.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026‑11‑04

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates a pre‑arranged sale schedule.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

President of Oncology sold 8,333 shares for $674K via a 10b5‑1 plan, reducing holdings to 3,946 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

The sale size is relatively small for a mid‑cap biotech and was pre‑arranged, limiting the strength of the signal.

Market effects

Minimal impact on the broader biotech sector; insider sales are routine and unlikely to shift sector sentiment.

No regional effect; the filing is US‑focused.

Low global relevance; limited to investors tracking Corcept Therapeutics.

Counterpoint

The sale could be purely liquidity‑driven under a 10b5‑1 plan, not reflecting any negative outlook on the company.

Key entities

  • Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics

  • Corcept Therapeutics Inc

    Biopharmaceutical company focused on cortisol‑related therapies

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.